SCHEMBL1701231

SCHEMBL1701231

Cc1cccc(NC(c2ccc([N+](=O)[O-])cc2)c2ccc3cccnc3c2O)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 3/20 0.75
TP53 P04637 4/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
ALDH1A1 P00352 2/20 0.71
CYP2C9 P11712 2/20 0.71
CYP2C19 P33261 2/20 0.71
HIF1A Q16665 2/20 0.71
RCE1 Q9Y256 1/20 0.71
MDM2 Q00987 6/20 0.70
HSP90AA1 P07900 1/20 0.68
MAPT P10636 3/20 0.66
KDM4E B2RXH2 1/20 0.60
LMNA P02545 1/20 0.60
TTR P02766 1/20 0.60
GAA P10253 1/20 0.60
HPGD P15428 1/20 0.60
ALOX12 P18054 1/20 0.60
RAB9A P51151 1/20 0.58
KMT2A Q03164 1/20 0.58
JMJD7 P0C870 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18131632 1.00 P4HB (0.75) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL18131634 1.00 P4HB (0.75) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL16501072 0.90 MAPT (0.74) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL15783089 0.87 TP53 (0.80) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL12064622 0.86 P4HB (0.72) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL2154029 0.86 P4HB (1.00) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL18197735 0.86 TP53 (0.79) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL13836546 0.85 MAPT (0.76) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL31023247 0.85 MAPT (0.76) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9
SCHEMBL15783090 0.85 SMN1; SMN2 (0.81) P4HBTP53SMN1; SMN2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US claimed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
EP-2566849-A1 8-HYDROXY-QUINOLINE DERIVATIVES "Avidin" Kutató, Fejleszt És Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2013-03-13 EP disclosed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO disclosed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES CYP2C8, NQO1, KEAP1 P4HB 1817/4885TP53 4173/4885SMN1; SMN2 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.